All In Biotech

Drug Trial Radar · NCT05501158

CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population

CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population (Pengaruh Genotipe CYP2D6 Terhadap Efektivitas Penggunaan Tamoksifen Untuk Pasien Kanker Payudara ER+ Pada Populasi Indonesia)

Last checked: Nov 19, 2026Latest source record: Aug 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Actual

Start

Jan 1, 2021

Primary completion

Apr 30, 2024

Study completion Jun 30, 2024

Sponsor

Lead sponsor
Nalagenetics Pte LtdIndustry
Sponsor type
Industry
Collaborators
SJH Initiatives; Universitas Indonesia; MRCCC Siloam Hospitals Semanggi
First posted
Aug 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been proven to be effective in the prevention and treatment of breast cancer. Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with reduced drug activity, while others do not have any pathological implications. The metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal, Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study (NCT04312347), the investigators recruited 150 breast cancer patients who were taking adjusted dose of tamoxifen daily based on their CYP2D6 phenotype. Although the investigators have measured the endoxifen level of the patients with adjusted treatment, the clinical outcomes of the study are not yet conclusive.

Conditions

  • Breast Cancer

Interventions

  • TamoxifenDrug

    Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival rateTime frame: 3 year
  2. Progression Survival rateTime frame: 3 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MRCCC Siloam Hospitals Semanggi

    Jakarta, DKI Jakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.